Genotype-Phenotype Correlation of Patients with Multiple Endocrine Neoplasia Type 2 in Japan

Japanese Journal of Clinical Oncology

Volumn 28, Issue 10, 1998, Pages 590-596

  Egawa, Shin Ichi ^a   Futami, Hitoyasu ^a   Takasaki, Kayo ^a   Iihara, Masatoshi ^b   Okamoto, Takahiro ^b   Kanbe, Masako ^b   Ohi, Toshitaka ^c   Saio, Yukie ^d   Miyauchi, Akira ^e   Takiyama, Yumi ^f   Koga, Masafumi ^g   Miyanaga, Ken ^h   Inoue, Ken Ichi ⁱ   Mitsuyama, Shoshu ^j   Nomura, Yoshio ^k   Takei, Hiroyuki ^l   Mugiya, Soichi ^m   Ishida, Osamu ⁿ   Zeze, Fujio ⁿ   Shakutsui, Shiro ^o   Inoue, Hiroyuki ^p   Oya, Hiroyuki ^q   Yoshimura, Akira ^r   Ishizuka, Shinji ^s   Tsujino, Takeshi ^t   Obara, Takao ^b   Yamaguchi, Ken ^a   more..

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^c Yaizu Municipal General Hospital   (Japan)

^d Gifu Red Cross Hospital   (Japan)

^e KUMA HOSPITAL   (Japan)

^f ASAHIKAWA MEDICAL COLLEGE   (Japan)

^g OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^h UNIVERSITY OF FUKUI   (Japan)

ⁱ SAITAMA CANCER CENTER   (Japan)

^j KITAKYUSHU MUNICIPAL MEDICAL CENTER   (Japan)

^k OITA UNIVERSITY   (Japan)

^l GUNMA UNIVERSITY   (Japan)

^m HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁿ UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^o Hyogo Prefecture Kaibara Hospital   (Japan)

^p UNIVERSITY OF TOKUSHIMA   (Japan)

^q Shinko Hospital   (Japan)

^r Niigata Prefectural Central Hospital   (Japan)

^s HIMEJI RED CROSS HOSPITAL   (Japan)

^t KOBE UNIVERSITY   (Japan)

more..

Author keywords

DNA testing; Genotype phenotype correlation; Multiple endocrine neoplasia; RET proto oncogene

Indexed keywords

DROSOPHILA PROTEIN; ONCOPROTEIN; PROTEIN RET; PROTEIN TYROSINE KINASE; RET ONCOGENE PROTEIN, DROSOPHILA;

ADRENAL TUMOR; ARTICLE; CLINICAL TRIAL; FEMALE; GENETICS; GENOTYPE; HUMAN; HYPERPARATHYROIDISM; MALE; MEDULLARY CARCINOMA; MULTICENTER STUDY; PHENOTYPE; PHEOCHROMOCYTOMA; POINT MUTATION; SIPPLE SYNDROME; THYROID TUMOR;

ADRENAL GLAND NEOPLASMS; CARCINOMA, MEDULLARY; DROSOPHILA PROTEINS; FEMALE; GENOTYPE; HUMANS; HYPERPARATHYROIDISM; MALE; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; PHENOTYPE; PHEOCHROMOCYTOMA; POINT MUTATION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-RET; RECEPTOR PROTEIN-TYROSINE KINASES; THYROID NEOPLASMS;

EID: 0032188092     PISSN: 03682811     EISSN: None     Source Type: Journal    
DOI: 10.1093/jjco/28.10.590     Document Type: Article

References (26)

1. Gardner DG. Recent advances in multiple endocrine neoplasia syndromes. Adv Intern Med 1997; 42.597-627.
2. Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RE et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasm type 2. International RET Mutation Consortium analysis. J Am Med Assoc 1996:19:1575-9.
3. Mulligan LM, Kwok JBJ, Healy CS, Elsdon MJ, Eng C, Gardner E, et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 1993,363:458-60.
4. Donis-Keller H, Dou S, Chi D, Carlson KM, Toshima K, Lairmore TC, et al. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 1993;2:851-6.
5. Carlson KM, Dou S, Chi D, Scavarda N, Toshima K, Jackson CE. et al. Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B. Proc Natl Acad Sci USA 1994;91:1579-83.
6. Eng C, Smith DP, Mulligan LM, Nagai MA, Healy CS, Fonder MA, et al. Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours. Hum Mol Genet 1994;3:237-41. Erratum: Hum Mol Genet 1994;3:686.
7. Lips CJM, Landsvater RM, Hoppener JWM, Geerdink RA, Blijham G, van Veen JMJS, et al. Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A. N Engl J Med 1994;331:828-35.
8. Wells SA Jr, Chi DD, Toshima K, Dehner LP, Coffin CM, Dowton SB, et al. Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A. Ann Surg 1994;220:237-50.
9. Iihara M, Yamashita T, Okamoto T, Kanbe M, Yamazaki K, Egawa S, et al. A nationwide clinical survey of patients with multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma in Japan. Jpn J Clin Oncol 1997;27:128-34.
10. Futami H, Egawa S, Yamaguchi K. A novel point mutation of the RET proto-oncogene in small cell lung carcinoma cell lines. Proc Jpn Acad 1994;70B.210-4.
11. Ceccerini I, Hofstra RMW, Luo Y, Stulp RP, Barone V, Stelwagen T, et al. DNA polymorphisms and conditions for SSCP analysis of the 20 exons of the RET proto-oncogene. Oncogene 1994;9:3025-9.
12. Orita M, Suzuki Y, Sekiya T, Hayashi K Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics 1989;5:874-9.
13. Moers AMJ, Landsvater RM, Schaap C, van Veen JSJM, de Valk IAJ, Bhjham GH, et al. Familial medullary thyroid carcinoma: Not a distinct entity? Genotype-phenotype correlation in a large family. Am J Med 1996;101:635-41.
14. Iwamoto T, Taniguchi M, Asai N, Ohkusu K, Nakashima I, Takahashi M. cDNA cloning of mouse ret proto-oncogene and its sequence similarity to the cadherin superfamily. Oncogene 1993;8:1087-91.
15. Lamiell JM, Salazar FG, Hsia YE. Von Hippel-Lindau disease affecting 43 members of a single kindred. Medicine 1989;68:1-29.
16. Crossey PA, Eng C, Ginalska-Malinowska M, Lennard TWJ, Wheeler DC, Ponder B AJ, et al. Molecular genetic diagnosis of von Hippel-Lindau disease in familial phaeochromocytoma J Med Genet 1995;32:885-6.
17. Neuman HPH, Eng C, Mulligan L, Glavac D, Zainer I, Ponder BAJ, et al. Consequences of direct genetic testing for germline mutatons in the clinical management of families with multiple endocrine neoplasia, type II.J Am Med Assoc 1995;14:1149-51.
18. Santoro M, Carlomagno F, Romano A, Bottaro DP, Dathan NA, Grieco M, et al. Activation of RET as a dominant transforming gene by germline mutations of MEN 2A and MEN 28. Science 1995;267:381-3.
19. Mulligan LM, Eng C, Attie T, Lyonnet S, Marsh DJ, Hyland VJ, et al. Diverse phenotypes associated with exon 10 mutations of the RET proto-oncogene. Hum Mol Genet 1994;3:2163-7.
20. Mulligan LM, Eng C, Healey CS, Clayton D, Kwok JB, Gardner E, et al. Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Nature Genet 1994;6:70-4.
21. Friling A, Drale H, Eng C, Raue F, Broelsch CE. Presymptomatic DNA screening in families with multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma. Surgery 1995;118:1099-104.
22. Marsh DJ, McDowall D, Hyland VJ, Andrew SD, Schnitzler M, Gaskin EL, et al. The identification of false positive responses to the pentagastrin stimulation test in RET mutation negative members of MEN 2A families. Clin Endocrinol 1996;44.213-20.
23. Pacini F, Romei C, Miccoli P, Elisei R, Molinaro E, Mancusi F, et al. Early treatment of hereditary medullary thyroid carcinoma after attribution of multiple endocrine neoplasia type 2 gene earner status by screening for ret gene mutations. Surgery 1995;118:1031-5.
24. Gill JR, Reyes-Mugica M, Lyengar S, Kidd KK, Touloukian RJ, Smith C, et al Early presentation of metastatic medullary carcinoma in multiple endocrine neoplasia type IIA: Implications for therapy. J Pediat 1996;129:459-64.
25. Skinner MA, DeBenedetti MK, Moley JF, Norton JA, Wells SA. Medullary thyroid carcinoma in children with multiple endocrine neoplasia type 2A and 2B. J Pediat Surg 1996;31:177-82.
26. Yamashita T, Iihara M, Okamoto J, Kanbe M, Ito Y, Kawakami M, et al. Treatment of minute medullary thyroid carcinoma in multiple endocrine neoplasia 2 A families first diagnosed by DNA analysis of RET proto-oncogene mutations: a case report Jpn J Clin Oncol 1997;27:42-5.